Compare Moderna, Inc. (MRNA) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vital Farms Inc — how do they compare? Moderna, Inc. trades at $224.87 (market cap $78.65B), while Vital Farms Inc trades at $9.37 (market cap $405.27M). The key difference: Moderna, Inc. is far larger — about 194.1× Vital Farms Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vital Farms Inc for 14 Days on average.
| MRNA | VITL | |
|---|---|---|
Market Cap | $78.65B | $405.27M |
Volume | 37,373,437 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $203.46 | $43.68 |
52-Week Low | $22.36 | $8.28 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $74.80B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Vital Farms (VITL) trades at $9.36, up 1.3% on the day, amid a challenging period marked by recent earnings misses and a bearish technical signal. The stock shows weak profitability with a net margin of 0.02% in 2026, though valuation ratios like P/E of 11.77 and P/S of 0.55 appear modest. Recent news highlights strategic review speculation and institutional buying interest, providing some positive sentiment against operational headwinds.
The outlook remains cautious due to earnings volatility and cash flow concerns, but analyst consensus is bullish with a $13.11 price target. Key risks include egg pricing pressure and execution challenges, while potential upside hinges on strategic moves and demand recovery for pasture-raised eggs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
